
Opinion|Videos|June 20, 2024
EV-302: Patient-Reported Outcomes from EV+Pembro in mUC
Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5







































